KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
KALA BIO (NASDAQ:KALA), a clinical-stage biopharmaceutical company focused on developing innovative eye disease treatments, will participate in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
KALA BIO (NASDAQ:KALA), a clinical-stage biopharmaceutical company focused on developing innovative eye disease treatments, will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The presentation is scheduled for September 10, 2025, at 2:00 p.m. ET in New York. Management will also be available for one-on-one meetings during the conference.
Investors can access the webcast and recording through the "Presentations" section on www.kalarx.com.
Details
News Market Reaction – KALA
On Sep 3, the day this news came out, KALA closed 23.13% above the previous close. That session’s volume was 3.9x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Sep 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ARLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held in New York, NY on Wednesday, September 10, 2025 at 2:00 p.m. ET. Management will be available for one-on-one meetings on Wednesday, September 10, 2025.
To access the webcast and subsequent archived recording of the presentation, please visit the “Presentations” section of the KALA website at www.kalarx.com.
About KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
Investor Contact:
Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.